TY - JOUR
T1 - Zika virus infection in pregnancy
T2 - A protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia
AU - Ades, A. E.
AU - Brickley, Elizabeth B.
AU - Alexander, Neal
AU - Brown, David
AU - Jaenisch, Thomas
AU - Miranda-Filho, Demócrito De Barros
AU - Pohl, Moritz
AU - Rosenberger, Kerstin D.
AU - Soriano-Arandes, Antoni
AU - Thorne, Claire
AU - Ximenes, Ricardo Arraes De Alencar
AU - De Araújo, Thalia Velho Barreto
AU - Avelino-Silva, Vivian I.
AU - Castillo, Sarah Esperanza Bethencourt
AU - Aburto, Victor Hugo Borja
AU - Brasil, Patrícia
AU - Christie, Celia D.C.
AU - De Souza, Wayner Vieira
AU - Gotuzzo H, Jose Eduardo
AU - Hoen, Bruno
AU - Koopmans, Marion
AU - Martelli, Celina Maria Turchi
AU - Martins Teixeira, Mauro
AU - Marques, Ernesto T.A.
AU - Miranda, Maria Consuelo
AU - Montarroyos, Ulisses Ramos
AU - Moreira, Maria Elisabeth
AU - Morris, J. Glenn
AU - Rockx, Barry
AU - Villarroel, Paola Mariela Saba
AU - Soria Segarra, Carmen
AU - Tami, Adriana
AU - Turchi, Marília Dalva
AU - Giaquinto, Carlo
AU - De Lamballerie, Xavier
AU - Wilder-Smith, Annelies
N1 - Funding Information:
Funding European Union Directorate-General for Research grant numbers 734 548 (ZIKAlliance), 734 584 (ZikaPLAN) and 734 857 (ZIKAction) Horizon 2020 programme of the European Commission. EBB was also supported by Wellcome Trust & the UK’s Department for International Development (205377/Z/16/Z to LCR; https://wellcome.ac.uk/).
Funding Information:
Competing interests All authors have completed the ICMJE uniform disclosure form. The following authors report grants from the European Commission (AEA, EBB, NA, DB, TJ, KDR, CT, CDCC, AS-A, JGM, CG, Xd-L, AW-S); EBB reports funding from by Wellcome Trust & the UK’s Department for International Development; MT reports grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil and from Fundacao de Amparo a Pesquisa do EStado de MInas Gerais (FAPEMIG, Brazil), during the conduct of the study; MK has a patent on zika diagnostics pending.
Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
PY - 2020/12/15
Y1 - 2020/12/15
N2 - Introduction Zika virus (ZIKV) infection in pregnancy has been associated with microcephaly and severe neurological damage to the fetus. Our aim is to document the risks of adverse pregnancy and birth outcomes and the prevalence of laboratory markers of congenital infection in deliveries to women experiencing ZIKV infection during pregnancy, using data from European Commission-funded prospective cohort studies in 20 centres in 11 countries across Latin America and the Caribbean. Methods and analysis We will carry out a centre-by-centre analysis of the risks of adverse pregnancy and birth outcomes, comparing women with confirmed and suspected ZIKV infection in pregnancy to those with no evidence of infection in pregnancy. We will document the proportion of deliveries in which laboratory markers of congenital infection were present. Finally, we will investigate the associations of trimester of maternal infection in pregnancy, presence or absence of maternal symptoms of acute ZIKV infection and previous flavivirus infections with adverse outcomes and with markers of congenital infection. Centre-specific estimates will be pooled using a two-stage approach. Ethics and dissemination Ethical approval was obtained at each centre. Findings will be presented at international conferences and published in peer-reviewed open access journals and discussed with local public health officials and representatives of the national Ministries of Health, Pan American Health Organization and WHO involved with ZIKV prevention and control activities.
AB - Introduction Zika virus (ZIKV) infection in pregnancy has been associated with microcephaly and severe neurological damage to the fetus. Our aim is to document the risks of adverse pregnancy and birth outcomes and the prevalence of laboratory markers of congenital infection in deliveries to women experiencing ZIKV infection during pregnancy, using data from European Commission-funded prospective cohort studies in 20 centres in 11 countries across Latin America and the Caribbean. Methods and analysis We will carry out a centre-by-centre analysis of the risks of adverse pregnancy and birth outcomes, comparing women with confirmed and suspected ZIKV infection in pregnancy to those with no evidence of infection in pregnancy. We will document the proportion of deliveries in which laboratory markers of congenital infection were present. Finally, we will investigate the associations of trimester of maternal infection in pregnancy, presence or absence of maternal symptoms of acute ZIKV infection and previous flavivirus infections with adverse outcomes and with markers of congenital infection. Centre-specific estimates will be pooled using a two-stage approach. Ethics and dissemination Ethical approval was obtained at each centre. Findings will be presented at international conferences and published in peer-reviewed open access journals and discussed with local public health officials and representatives of the national Ministries of Health, Pan American Health Organization and WHO involved with ZIKV prevention and control activities.
UR - http://www.scopus.com/inward/record.url?scp=85098534238&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2019-035307
DO - 10.1136/bmjopen-2019-035307
M3 - Article
C2 - 33323426
AN - SCOPUS:85098534238
SN - 2044-6055
VL - 10
JO - BMJ Open
JF - BMJ Open
IS - 12
M1 - e035307
ER -
